Replies to post #137693 on Biotech Values

[oc631]

I personally didn't see anything troubling about the safety data at all except for the known cleft issue.

There were two Qnexa patients that had heart attacks and a high rate of non-responders (25%?) which draws attention to the risk benefit of premature approval.